Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?
作者： Antonio Passaro , Enrico Cortesi , Filippo de Marinis
DOI: 10.1586/ERA.11.120
关键词:
摘要: After first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC), many patients remain candidates a second-line treatment. Docetaxel, pemetrexed and erlotinib are currently approved in the USA Europe as therapy NSCLC, while gefitinib is licensed Europe, but not USA, EGF receptor-mutated same setting. Results of registration trials these four agents show similar efficacy terms objective response rate survival, significantly different toxicity tolerability. Therefore, at time failure treatment, it crucial to evaluate clinical factors that could help choose treatment metastatic performance status comorbidities; new predictive biomarkers will be validated future trials. Considering prognostic factors, tyrosine kinase inhibitors valid option NSCLC.
core.ac.uk
elsevier.com
informahealthcare.com参考文章(79)
Frank V. Fossella, Russell DeVore, Ronald N. Kerr, Jeffrey Crawford, Ronald R. Natale, Frank Dunphy, Leonard Kalman, Vincent Miller, Jin Soo Lee, Melvin Moore, David Gandara, Daniel Karp, Everett Vokes, Mark Kris, Yong Kim, Francis Gamza, Luz Hammershaimb, , Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Journal of Clinical Oncology. ,vol. 18, pp. 2354- 2362 ,(2000) , 10.1200/JCO.2000.18.12.2354
M J Brady, D F Cella, F Mo, A E Bonomi, D S Tulsky, S R Lloyd, S Deasy, M Cobleigh, G Shiomoto, Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. Journal of Clinical Oncology. ,vol. 15, pp. 974- 986 ,(1997) , 10.1200/JCO.1997.15.3.974
F R Hirsch, M Varella-Garcia, F Cappuzzo, Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene. ,vol. 28, ,(2009) , 10.1038/ONC.2009.199
Frances A Shepherd, Second-line chemotherapy for non-small cell lung cancer. Expert Review of Anticancer Therapy. ,vol. 3, pp. 435- 442 ,(2003) , 10.1586/14737140.3.4.435
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
Antonio Rossi, Paolo Maione, Giuseppe Colantuoni, Carmine Ferrara, Emanuela Rossi, Ciro Guerriero, Dario Nicolella, Marzia Falanga, Giovanni Palazzolo, Cesare Gridelli, Recent developments of targeted therapies in the treatment of non-small cell lung cancer. Current Drug Discovery Technologies. ,vol. 6, pp. 91- 102 ,(2009) , 10.2174/157016309788488339
Chandra P. Belani, The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. Cancer Investigation. ,vol. 28, pp. 413- 423 ,(2010) , 10.3109/07357901003631072
A Wailoo, A Sutton, A Morgan, The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis British Journal of Cancer. ,vol. 100, pp. 436- 441 ,(2009) , 10.1038/SJ.BJC.6604863
Rafael Rosell, Miquel Taron, Jose Javier Sanchez, Luis Paz-Ares, None, Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncology. ,vol. 3, pp. 277- 283 ,(2007) , 10.2217/14796694.3.3.277
D CELLA, D ETON, D FAIRCLOUGH, P BONOMI, A HEYES, C SILBERMAN, M WOLF, D JOHNSON, What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. Journal of Clinical Epidemiology. ,vol. 55, pp. 285- 295 ,(2002) , 10.1016/S0895-4356(01)00477-2